REPORTS

Let’s Pullulate and Expand Your Business

Androgen Deprivation Therapy (Adt) Market - Global Professional Analysis and Forecast to 2026

Oct 10, 2019  |  150 PAGES  |  REPORT CODE: CMM202757
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Androgen Deprivation Therapy (Adt) market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 14.4% during the forecast period.

This report presents the market size and development trends by detailing the Androgen Deprivation Therapy (Adt) market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Androgen Deprivation Therapy (Adt) market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Androgen Deprivation Therapy (Adt) industry and will help you to build a panoramic view of the industrial development.

Androgen Deprivation Therapy (Adt) Market, By Type:

  • Type 1

  • Type 2

  • Type 3

Androgen Deprivation Therapy (Adt) Market, By Application:

  • End-Users 1

  • End-Users 2

  • End-Users 3

Some of the leading players are as follows:

  • Dendreon Corporation (USA)

  • F. Hoffmann-La Roche Ltd. (Switzerland)

  • ALZA Corporation (USA)

  • Sanofi-Aventis SA (France)

  • Cell Genesys Inc. (USA)

  • GlaxoSmithKline Plc (UK)

  • Immunomedics, Inc. (USA)

  • AstraZeneca PLC (UK)

  • Pfizer Inc. (USA)

  • Spectrum Pharmaceuticals, Inc. (USA)

  • Takeda Pharmaceutical Company Limited (Japan)

  • Paladin Labs Inc. (Canada)

  • Progenics Pharmaceuticals, Inc. (USA)

  • Novartis AG (Switzerland)

  • Genentech Inc. (USA)

  • OSI Pharmaceuticals, Inc. (USA)

  • Amgen Inc. (USA)

  • Bristol-Myers Squibb Company (USA)

  • EUSA Pharma, (USA) Inc. (USA)

  • Abbott Laboratories (USA)

  • Medimmune, LLC (USA)

  • Indevus Pharmaceuticals Inc. (USA)

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Androgen Deprivation Therapy (Adt) Market: Technology Type Analysis

  • 4.1 Androgen Deprivation Therapy (Adt) Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Androgen Deprivation Therapy (Adt) Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Type 1

    • 4.3.2 Type 2

    • 4.3.3 Type 3

5 Androgen Deprivation Therapy (Adt) Market: Product Analysis

  • 5.1 Androgen Deprivation Therapy (Adt) Product Market Share Analysis, 2018 & 2026

  • 5.2 Androgen Deprivation Therapy (Adt) Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Androgen Deprivation Therapy (Adt) Market: Application Analysis

  • 6.1 Androgen Deprivation Therapy (Adt) Application Market Share Analysis, 2018 & 2026

  • 6.2 Androgen Deprivation Therapy (Adt) Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 End-User 1

    • 6.3.2 End-User 1

    • 6.3.3 End-User 3

7 Androgen Deprivation Therapy (Adt) Market: Regional Analysis

  • 7.1 Androgen Deprivation Therapy (Adt) Regional Market Share Analysis, 2018 & 2026

  • 7.2 Androgen Deprivation Therapy (Adt) Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Dendreon Corporation (USA)

    • 9.1.1 Dendreon Corporation (USA) Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 F. Hoffmann-La Roche Ltd. (Switzerland)

    • 9.2.1 F. Hoffmann-La Roche Ltd. (Switzerland) Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 ALZA Corporation (USA)

    • 9.3.1 ALZA Corporation (USA) Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Sanofi-Aventis SA (France)

    • 9.4.1 Sanofi-Aventis SA (France) Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Cell Genesys Inc. (USA)

    • 9.5.1 Cell Genesys Inc. (USA) Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 GlaxoSmithKline Plc (UK)

    • 9.6.1 GlaxoSmithKline Plc (UK) Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Immunomedics, Inc. (USA)

    • 9.7.1 Immunomedics, Inc. (USA) Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 AstraZeneca PLC (UK)

    • 9.8.1 AstraZeneca PLC (UK) Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Pfizer Inc. (USA)

    • 9.9.1 Pfizer Inc. (USA) Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Spectrum Pharmaceuticals, Inc. (USA)

    • 9.10.1 Spectrum Pharmaceuticals, Inc. (USA) Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Takeda Pharmaceutical Company Limited (Japan)

    • 9.11.1 Takeda Pharmaceutical Company Limited (Japan) Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Paladin Labs Inc. (Canada)

    • 9.12.1 Paladin Labs Inc. (Canada) Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Progenics Pharmaceuticals, Inc. (USA)

    • 9.13.1 Progenics Pharmaceuticals, Inc. (USA) Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Novartis AG (Switzerland)

    • 9.14.1 Novartis AG (Switzerland) Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 Genentech Inc. (USA)

    • 9.15.1 Genentech Inc. (USA) Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 OSI Pharmaceuticals, Inc. (USA)

    • 9.16.1 OSI Pharmaceuticals, Inc. (USA) Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 Amgen Inc. (USA)

    • 9.17.1 Amgen Inc. (USA) Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 Bristol-Myers Squibb Company (USA)

    • 9.18.1 Bristol-Myers Squibb Company (USA) Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

  • 9.19 EUSA Pharma, (USA) Inc. (USA)

    • 9.19.1 EUSA Pharma, (USA) Inc. (USA) Company overview

    • 9.19.2 Financial performance

    • 9.19.3 Product benchmarking

    • 9.19.4 Strategic initiatives

    • 9.19.5 SWOT analysis

  • 9.20 Abbott Laboratories (USA)

    • 9.20.1 Abbott Laboratories (USA) Company overview

    • 9.20.2 Financial performance

    • 9.20.3 Product benchmarking

    • 9.20.4 Strategic initiatives

    • 9.20.5 SWOT analysis

  • 9.21 Medimmune, LLC (USA)

    • 9.21.1 Medimmune, LLC (USA) Company overview

    • 9.21.2 Financial performance

    • 9.21.3 Product benchmarking

    • 9.21.4 Strategic initiatives

    • 9.21.5 SWOT analysis

  • 9.22 Indevus Pharmaceuticals Inc. (USA)

    • 9.22.1 Indevus Pharmaceuticals Inc. (USA) Company overview

    • 9.22.2 Financial performance

    • 9.22.3 Product benchmarking

    • 9.22.4 Strategic initiatives

    • 9.22.5 SWOT analysis

 

The List of Tables and Figures (Totals 90 Figures and 163 Tables)

  • Figure Type 1 Androgen Deprivation Therapy (Adt) market, 2015 - 2026 (USD Million)

  • Figure Type 2 Androgen Deprivation Therapy (Adt) market, 2015 - 2026 (USD Million)

  • Figure Type 3 Androgen Deprivation Therapy (Adt) market, 2015 - 2026 (USD Million)

  • Figure End-Users 1 market, 2015 - 2026 (USD Million)

  • Figure End-Users 2 market, 2015 - 2026 (USD Million)

  • Figure End-Users 3 market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Androgen Deprivation Therapy (Adt) market, by country, 2015 - 2026 (USD Million)

  • Table North America Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table North America Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table North America Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Canada Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Canada Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Europe Androgen Deprivation Therapy (Adt) market, by country, 2015 - 2026 (USD Million)

  • Table Europe Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Europe Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Europe Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Germany Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Germany Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table France Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table France Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Italy Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Italy Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Spain Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Spain Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Androgen Deprivation Therapy (Adt) market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table China Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table China Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Japan Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Japan Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table India Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table India Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Androgen Deprivation Therapy (Adt) market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table MEA Androgen Deprivation Therapy (Adt) market, by country, 2015 - 2026 (USD Million)

  • Table MEA Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table MEA Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table MEA Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Androgen Deprivation Therapy (Adt) market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Androgen Deprivation Therapy (Adt) market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Androgen Deprivation Therapy (Adt) market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Dendreon Corporation (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table F. Hoffmann-La Roche Ltd. (Switzerland) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table ALZA Corporation (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi-Aventis SA (France) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Cell Genesys Inc. (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table GlaxoSmithKline Plc (UK) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Immunomedics, Inc. (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca PLC (UK) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Inc. (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Spectrum Pharmaceuticals, Inc. (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Takeda Pharmaceutical Company Limited (Japan) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Paladin Labs Inc. (Canada) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Progenics Pharmaceuticals, Inc. (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis AG (Switzerland) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Genentech Inc. (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table OSI Pharmaceuticals, Inc. (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Amgen Inc. (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bristol-Myers Squibb Company (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table EUSA Pharma, (USA) Inc. (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Abbott Laboratories (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Medimmune, LLC (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Indevus Pharmaceuticals Inc. (USA) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top